Artemis Pharma to Use Benitec s ddRNAi Technology for Mouse and Rat Models | GenomeWeb

NEW YORK, Oct. 28 (GenomeWeb News) - Benitec said today that it has granted a worldwide non-exclusive license to Artemis Pharmaceuticals for use of its proprietary ddRNAi technology in transgenic mouse and rat model development.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.